IPA ImmunoPrecise Antibodies
- 1.120
- -0.028-2.46%
- 1.140
- +0.020+1.79%
ImmunoPrecise Antibodies News
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
VICTORIA, BC / ACCESSWIRE/ April 12, 2024 / InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability and speed challenges partnered with
InterSystems and IPA's Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search With LENSai for AI-Driven Healthcare Applications
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga Co's Subsidiary BioStrand And InterSystems Announce A Collaboration For AI-Driven Healthcare Applications
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga Co's Subsidiary BioStrand And InterSystems Announce A Collaboration For AI-Driven Healthcare Applications
ImmunoPrecise Antibodies Acquires Carterra LSA Instrument
Press Release: IPA Acquires the Carterra LSA(R) Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
IPA Acquires the Carterra LSA(R) Instrument to Enhance Antibody Discovery and Bolster Its AI Developments Significant throughput of LSA to advance IPA's diversity- and data-driven drug development an
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2024 Earnings Call Transcript
ImmunoPrecise Antibodies Price Target Maintained With a $5.00/Share by Benchmark
ImmunoPrecise Antibodies Price Target Maintained With a $5.00/Share by Benchmark
HC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $9 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ImmunoPrecise Antibodies (NASDAQ:IPA) with a Buy and maintains $9 price target.
ImmunoPrecise Antibodies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 480.61% HC Wainwright & Co. → $9 Reiterates Buy → Buy 09/18/2023 480.61% HC Wainwright & Co. →
Buy Rating Affirmed: ImmunoPrecise Antibodies' Growth and Innovation Drive Positive Outlook
Earnings Call: IPA Sees 20% Revenue Rise Amid Strategic Expansions
ImmunoPrecise Antibodies (IPA) has reported a 20% increase in total revenue year-over-year for the third quarter of fiscal year 2024, despite a challenging macroeconomic climate.
Earnings Call Summary | ImmunoPrecise Antibodies(IPA.US) Q3 2024 Earnings Conference
The following is a summary of the ImmunoPrecise Antibodies Ltd. (IPA) Q3 2024 Earnings Call Transcript:Financial Performance:ImmunoPrecise reported a Q3 2024 revenue of $6.2 million, a 20.3% increase
ImmunoPrecise Antibodies Q3 EPS $(0.11) Misses $(0.07) Estimate, Sales $6.22M Beat $4.50M Estimate
ImmunoPrecise Antibodies Q3 EPS $(0.11) Misses $(0.07) Estimate, Sales $6.22M Beat $4.50M Estimate
ImmunoPrecise GAAP EPS of -C$0.11, Revenue of C$6.2M
Press Release: IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* IPA reports a fourth consecutive quarter of increased revenue. VICTORIA, British Columbia--(BUSINESS
ImmunoPrecise Antibodies 3Q Rev $6.2M >IPA
ImmunoPrecise Antibodies 3Q Rev $6.2M >IPA
Earnings Outlook For ImmunoPrecise Antibodies
ImmunoPrecise Antibodies (NASDAQ:IPA) is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Here's what investors need to know before the announcement.Analysts estimate that Imm
BREA, MSAI and APM Among Pre-market Losers
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology
VICTORIA, BC / ACCESSWIRE / March 8, 2024 / Anyone familiar with the intricacies of life science knows how truly complicated DNA is; without a full understanding of the language of DNA, scientists are
Analysis
Price Target
No Data
